518 related articles for article (PubMed ID: 27729630)
1. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
3. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.
Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D
J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer.
Liu S; Wang M; Zheng C; Zhong Q; Shi Y; Han X
Clin Biochem; 2020 May; 79():54-60. PubMed ID: 32087138
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis.
Jia X; Liu J; Gao Y; Huang Y; Du Z
Arch Med Res; 2014 Oct; 45(7):580-8. PubMed ID: 25446613
[TBL] [Abstract][Full Text] [Related]
6. GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma.
Attallah AM; El-Far M; Omran MM; Abdelrazek MA; Attallah AA; Saeed AM; Farid K
Tumour Biol; 2016 Sep; 37(9):12571-12577. PubMed ID: 27380057
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma.
Lee HJ; Yeon JE; Suh SJ; Lee SJ; Yoon EL; Kang K; Yoo YJ; Kim JH; Seo YS; Yim HJ; Byun KS
Gut Liver; 2014 Mar; 8(2):177-85. PubMed ID: 24672660
[TBL] [Abstract][Full Text] [Related]
8. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.
Xu C; Yan Z; Zhou L; Wang Y
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1417-24. PubMed ID: 23743582
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
[TBL] [Abstract][Full Text] [Related]
10. Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma.
Yu JP; Xu XG; Ma RJ; Qin SN; Wang CR; Wang XB; Li M; Li MS; Ma Q; Xu WW
J Clin Lab Anal; 2015 Mar; 29(2):85-93. PubMed ID: 24687454
[TBL] [Abstract][Full Text] [Related]
11. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.
Wang Y; Yang H; Xu H; Lu X; Sang X; Zhong S; Huang J; Mao Y
J Gastroenterol Hepatol; 2014 Mar; 29(3):597-602. PubMed ID: 24236824
[TBL] [Abstract][Full Text] [Related]
12. Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis.
Xu D; Su C; Sun L; Gao Y; Li Y
Ann Hepatol; 2019; 18(1):58-67. PubMed ID: 31113610
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients.
Li B; Liu H; Shang HW; Li P; Li N; Ding HG
Afr Health Sci; 2013 Sep; 13(3):703-9. PubMed ID: 24250310
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
[TBL] [Abstract][Full Text] [Related]
15. The Value of GPC3 and GP73 in Clinical Diagnosis of Hepatocellular Carcinoma.
Jing JS; Ye W; Jiang YK; Ma J; Zhu MQ; Ma JM; Zhou H; Yu LQ; Yang YF; Wang SC
Clin Lab; 2017 Nov; 63(11):1903-1909. PubMed ID: 29226636
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma.
Ozkan H; Erdal H; Koçak E; Tutkak H; Karaeren Z; Yakut M; Köklü S
J Clin Lab Anal; 2011; 25(5):350-3. PubMed ID: 21919070
[TBL] [Abstract][Full Text] [Related]
18. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians.
Gomaa SH; Abaza MM; Elattar HA; Amin GA; Elshahawy DM
Arab J Gastroenterol; 2020 Dec; 21(4):224-232. PubMed ID: 32891543
[TBL] [Abstract][Full Text] [Related]
19. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
[TBL] [Abstract][Full Text] [Related]
20. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.
Cao B; Yang L; Rong W; Feng L; Han N; Zhang K; Cheng S; Wu J; Xiao T; Gao Y
Int J Clin Exp Pathol; 2015; 8(12):16046-54. PubMed ID: 26884881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]